http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100392692-B1

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C261-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C01C3-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-02
filingDate 2001-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2003-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2003-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-100392692-B1
titleOfInvention A Method for the Preparation of Epinastine and a Pharmaceutically Acceptable Salt thereof
abstract The present invention relates to a novel process for preparing epiastine and its pharmaceutically acceptable salts.n n n Epineast is a 9,13b-dihydro-1H-dibenz [c, f] imidazole [1,5-a] azin-3-amine (9,13b-dihydro-1H-dibenz [c, f] A short name for imidazole [1,5-a] azepine-3-amine), the hydrochloride treats or prevents pain, especially chronic or infection-induced pain, and especially migraines.n n n In the present invention, cyanogen bromide, bromine, and N-methyl-benzylamine are added to 6-aminomethyl-6,11-dihydro-5H-dibenz [b, e] azepine, which is a compound of formula (II). Instead of the reaction, cyanamide or potassium cyanate is reacted to produce epinastine, thereby preventing the generation of highly toxic hydrogen bromide gas, which is a problem of the prior art, and reacting in aqueous solution instead of conventional ethanol and organic solvent solutions to produce epinastine. As a result, the reaction was stabilized, the resulting solid phase was easily separated and the yield was increased by about 10%.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021025442-A1
priorityDate 2001-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2001064282-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2001131177-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5312916-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID260
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419502566
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3241
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556587
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419546850
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557048
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9877894
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID413471277
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9864
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412224690
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18755303
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6451476
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421914966
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11378442
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419487428
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419545319
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24408
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7669
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419523398
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21885
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID104770
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559198
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410472318
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559213
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10476
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID795
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559170
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419545923

Total number of triples: 47.